Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > luvhorses just stop!!! I'm a long for at least another year
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Post by DigitalSpurson Jul 13, 2020 1:41pm
170 Views
Post# 31261336

luvhorses just stop!!! I'm a long for at least another year

luvhorses just stop!!! I'm a long for at least another yearWe get it - you got burned and sold

I was averaging 49 cents a share early on - avg down now to 32 cents on about $5k invested

I'm not letting go because this baby is loading up like a spring right now - let me tell you this won't be heading down anytime soon and you can expect some HUGE results by end of year.

I don't flip and see this as a diamond in the rough right now. Management did what management has to do for the long term success of the company

Tough decision need to take place, money is needed and maybe more tough decision down the road.

I don't see any more PPs under 30 cents, that's for sure - but I can say I am fully invested and will be watching from time to time


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities